Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


Phase III TRuE-AD3 study of Opzelura meets primary endpoint in atopic dermatitis – Incyte

Written by | 20 Jul 2023

Incyte announced positive topline results from its randomized, vehicle-controlled, pivotal Phase III TRuE-AD3 study evaluating the safety and efficacy of Opzelura (ruxolitinib cream) in children (age at least… read more.

The right moisturiser for children with eczema is the one that they like to use, study finds

Written by | 29 May 2022

The Best Emollients for Eczema trial has found that no one type of moisturiser is better than another.  This study, the first in the world to directly compare… read more.

Cibinqo recommended for approval by CHMP for atopic dermatitis – Pfizer

Written by | 4 Jan 2022

Pfizer announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the 100 mg and 200 mg… read more.

UK MHRA grants marketing authorisation for Cibinqo for adults and adolescents with moderate to severe atopic dermatitis – Pfizer

Written by | 22 Sep 2021

Pfizer Inc. announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted Great Britain marketing authorization for Cibinqo (abrocitinib), an oral, once-daily, Janus kinase 1… read more.

Lilly and Incyte provide update on supplemental NDA for baricitinib for the treatment of moderate to severe atopic dermatitis

Written by | 24 Jul 2021

Eli Lilly and Company and Incyte announced that the FDA will not meet the Prescription Drug User Fee Act (PDUFA) action date for the supplemental new drug application… read more.

EU approves Adtralza for moderate-to-severe atopic dermatitis – LEO Pharma

Written by | 28 Jun 2021

LEO Pharma announced that the European Commission (EC) has approved Adtralza (tralokinumab) for the treatment of moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic therapy…. read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.